The current price of ARWR is $57.46 — it has decreased by 6.80% since the previous close. Data as of Nov 5, 2026.
ARWR is down 3.83% over the past week, down 7.84% over the past month and up 42.55% over the past year. The price is below its 200-day moving average of $71.66.
Analysts' average 12-month price target for ARWR is $101.56, which implies 76.75% upside from the current price. Individual estimates range from $46.00 to $126.00.
Of the 15 analysts covering Arrowhead Pharmaceuticals, Inc., 4 rate it a strong buy, 10 rate it a buy and 1 rates it a hold. The overall consensus is bullish. Analyst ratings are opinions and do not guarantee future performance.
Arrowhead Pharmaceuticals, Inc. has a market capitalization of $8.12B. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.
In its most recent quarterly report, Arrowhead Pharmaceuticals, Inc. posted a loss of $1.36 per share against an estimate of -$1.28, missing expectations by 6.25%. Upcoming reports are listed in the earnings calendar.
Arrowhead Pharmaceuticals, Inc. reported revenue of $75.25M in its most recent quarter, which has increased by 171.02% compared with the same quarter a year earlier. Analysts had expected $44.17M.
Arrowhead Pharmaceuticals, Inc. has not paid any dividends over the past year.
In the latest trading session ARWR moved between $57.24 and $61.73, a range of 7.82% of its current price.
Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of Arrowhead Pharmaceuticals, Inc. shows a strong sell rating today and a sell rating on the weekly timeframe. Technical ratings are indicators, not investment advice.
Over the past 52 weeks ARWR has traded between $37.06 and $95.49. The current price is 39.83% below its 52-week high.
Figures as of Nov 5, 2026. This information is provided for general purposes only and is not investment advice.